Oncotelic Therapeutics (OTCQB: OTLC) and its wholly owned subsidiary Pet2DAO, Inc. announced that its PDAOAI artificial intelligence-powered drug discovery platform is inviting scientists, AI developers, and biotech founders to participate in BIO REBOOT. The initiative allows participants to bring research questions, technical expertise, and drug discovery ideas to the PDAOAI community, with selected projects potentially considered for startup funding and Oncotelic support covering validation, formulation, regulatory planning, and clinical development. The move underscores a growing trend of open innovation in biotechnology, where AI platforms are used to crowdsource and accelerate early-stage drug discovery. For investors and industry watchers, this signals Oncotelic's efforts to expand its pipeline beyond internal programs and potentially create new revenue streams through partnerships and equity stakes in emerging biotech ventures.
In addition, Oncotelic announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, scheduled for Oct. 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study illustrating how Partitioned Literature Aggregation generated a candidate four-gene signature. Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development. These presentations will showcase the platform's capabilities to a global audience of researchers and industry leaders, potentially attracting new collaborators and validating the technology's utility in real-world drug discovery. The case study on hepatocellular carcinoma, a cancer with limited treatment options, highlights the platform's focus on areas of high unmet need. If the four-gene signature proves viable, it could lead to new diagnostic or therapeutic approaches, benefiting patients and positioning Oncotelic as a key player in AI-driven oncology research.
Oncotelic Therapeutics develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The company also develops the PDAOAI platform to support its work in drug discovery and development. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. The full press release can be viewed at https://ibn.fm/dxB7y.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, and social media distribution via IBN to millions of followers. For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
